Limited Adipose Tissue Expandability as a Risk Factor for Development of Type 2 Diabetes: the Role of Preadipocytes
The LIMEX study, sponsored by Charles University, investigates the role of preadipocytes in adipose tissue expandability and its implications for type 2 diabetes (T2DM) risk. Given the rising prevalence of T2DM globally, understanding the genetic and metabolic factors influencing adipose tissue behavior could lead to novel therapeutic strategies. The findings may inform the development of targeted interventions or drugs aimed at enhancing adipogenic capacity and improving insulin sensitivity, potentially capturing a significant share of the diabetes management market. The competitive landscape includes existing diabetes therapies and emerging treatments focusing on metabolic health, necessitating thorough diligence on potential partnerships or licensing opportunities.
Indication: Type2 Diabetes Mellitus
Modality: RNA therapy
Target: Preadipocytes and adipose tissue expandability mechanisms related to insulin sensitivity and type 2 diabetes development.
Sponsor: Charles University, Czech Republic
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 10, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Preadipocytes and adipose tissue expandability mechanisms related to insulin sensitivity and type 2 diabetes development.
View original source fields
Condition raw: Type2 Diabetes Mellitus
Condition normalized: Type2 Diabetes Mellitus
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: Preadipocytes and adipose tissue expandability mechanisms related to insulin sensitivity and type 2 diabetes development.
Target normalized: Preadipocytes and adipose tissue expandability mechanisms related to insulin sensitivity and type 2 diabetes development.